Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany

The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Skalt, Daniela, Moertl, Bernhard, von Bergwelt-Baildon, Michael, Schmidt, Christian, Schoel, Wolfgang, Bücklein, Veit, Weiglein, Tobias, Dreyling, Martin, Berger, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257301/
https://www.ncbi.nlm.nih.gov/pubmed/35813101
http://dx.doi.org/10.1097/HS9.0000000000000736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257301/
https://www.ncbi.nlm.nih.gov/pubmed/35813101
http://dx.doi.org/10.1097/HS9.0000000000000736

Ejemplares similares